MX2019010898A - Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer. - Google Patents

Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer.

Info

Publication number
MX2019010898A
MX2019010898A MX2019010898A MX2019010898A MX2019010898A MX 2019010898 A MX2019010898 A MX 2019010898A MX 2019010898 A MX2019010898 A MX 2019010898A MX 2019010898 A MX2019010898 A MX 2019010898A MX 2019010898 A MX2019010898 A MX 2019010898A
Authority
MX
Mexico
Prior art keywords
compounds
salts
quinolin
relates
formula
Prior art date
Application number
MX2019010898A
Other languages
English (en)
Spanish (es)
Inventor
Christophe Barlaam Bernard
Gordon Pike Kurt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2019010898A publication Critical patent/MX2019010898A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019010898A 2017-03-16 2018-03-15 Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer. MX2019010898A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16
PCT/EP2018/056516 WO2018167203A1 (en) 2017-03-16 2018-03-15 Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
MX2019010898A true MX2019010898A (es) 2019-11-07

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010898A MX2019010898A (es) 2017-03-16 2018-03-15 Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer.

Country Status (25)

Country Link
US (2) US20200087300A1 (OSRAM)
EP (1) EP3596076A1 (OSRAM)
JP (1) JP2020514344A (OSRAM)
KR (1) KR20190129923A (OSRAM)
CN (1) CN110431139B (OSRAM)
AU (1) AU2018234985B2 (OSRAM)
BR (1) BR112019018723A2 (OSRAM)
CA (1) CA3055258A1 (OSRAM)
CL (1) CL2019002527A1 (OSRAM)
CO (1) CO2019010029A2 (OSRAM)
CR (1) CR20190429A (OSRAM)
DO (1) DOP2019000228A (OSRAM)
EA (1) EA038233B1 (OSRAM)
EC (1) ECSP19066134A (OSRAM)
IL (1) IL269272A (OSRAM)
JO (1) JOP20190209A1 (OSRAM)
MA (1) MA49884A (OSRAM)
MX (1) MX2019010898A (OSRAM)
NI (1) NI201900094A (OSRAM)
PE (1) PE20191486A1 (OSRAM)
PH (1) PH12019502086A1 (OSRAM)
SG (1) SG11201908065YA (OSRAM)
TW (1) TW201843151A (OSRAM)
UA (1) UA124554C2 (OSRAM)
WO (1) WO2018167203A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes
TW202340189A (zh) * 2022-01-26 2023-10-16 大陸商正大天晴藥業集團股份有限公司 含有肼基的化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
AU2010255727B2 (en) * 2009-06-04 2013-02-28 Novartis Ag 1H-imidazo[4,5-c]quinolinone derivatives
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药(上海)有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (OSRAM) * 2014-05-08 2018-04-21
HUE054745T2 (hu) * 2015-04-02 2021-09-28 Merck Patent Gmbh Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Also Published As

Publication number Publication date
NI201900094A (es) 2020-03-18
MA49884A (fr) 2020-06-24
CL2019002527A1 (es) 2019-11-22
CN110431139A (zh) 2019-11-08
EA201992090A1 (ru) 2020-03-06
TW201843151A (zh) 2018-12-16
DOP2019000228A (es) 2019-09-30
WO2018167203A1 (en) 2018-09-20
US20200087300A1 (en) 2020-03-19
ECSP19066134A (es) 2019-09-30
BR112019018723A2 (pt) 2020-04-07
CO2019010029A2 (es) 2019-09-30
IL269272A (en) 2019-11-28
JOP20190209A1 (ar) 2019-09-12
UA124554C2 (uk) 2021-10-05
CA3055258A1 (en) 2018-09-20
SG11201908065YA (en) 2019-09-27
AU2018234985A1 (en) 2019-10-24
EP3596076A1 (en) 2020-01-22
EA038233B1 (ru) 2021-07-28
JP2020514344A (ja) 2020-05-21
US20210347775A1 (en) 2021-11-11
KR20190129923A (ko) 2019-11-20
AU2018234985B2 (en) 2020-04-02
CR20190429A (es) 2019-11-12
PH12019502086A1 (en) 2020-03-09
PE20191486A1 (es) 2019-10-18
CN110431139B (zh) 2022-07-05

Similar Documents

Publication Publication Date Title
MX2019010898A (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer.
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
CR20200620A (es) Compuestos de purinona y su uso en el tratamiento del cáncer campo
PH12020551572A1 (en) Heterocyclic compounds as immunomodulators
TN2016000458A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer.
CR20200614A (es) Compuestos heterocíclicos como inmunomoduladores
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX376465B (es) Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret.
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021011811A (es) Protacs que degradan el receptor de estrogeno.
MY192861A (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
EP4342473A3 (en) Compounds useful in hiv therapy
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
WO2019199667A3 (en) Pladienolide compounds and their use
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors
FR3028762B1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine